News >

Tisagenlecleucel Approved in Europe for DLBCL, ALL

Jason M. Broderick @jasoncology
Published: Monday, Aug 27, 2018

Carl June, MD

Carl June, MD

The European Commission has approved tisagenlecleucel (Kymriah) for the treatment of either adult patients with diffuse large B-cell lymphoma (DLBCL) that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse posttransplant, or in second or later relapse, according to Novartis, the manufacturer of the CAR T-cell therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication